The anti-inflammatory drug hydroxychloroquine does not significantly reduce admission to intensive care or death in patients hospitalized with pneumonia due to COVID-19, finds a study from France. And a randomized clinical trial from China shows that hospitalized patients with mild to moderate persistent covid-19 who received hydroxychloroquine did not clear the virus more quickly than those receiving standard care.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/05/200515174441.htm
No comments:
Post a Comment